

**Kenneth Leong**

(603) 7890 8888 (ext 2093)

[kenneth.leong@apexsecurities.com.my](mailto:kenneth.leong@apexsecurities.com.my)



**Technical Commentary:**

Price has established the uptrend formation in September 2024 since recovering above SMA200. After charging sharply higher in recent months, price experienced a mild pullback and briefly dipped below EMA20. Price staged a swift recovery lately and formed a short-term flag-formation breakout above RM3.49. Price may advance to target the next resistances located at **RM3.67-RM3.80**. Downside wise, support is pegged at **RM3.38**.

<b>Sarawak Oil Palms Bhd (5126)</b>		
Board: MAIN	Shariah: Yes	Sector: Agricultural Products & Servic
Trend: ☆☆☆☆	Momentum: ★★★★★	Strength: ★★★★★
R1: RM3.670 (+3.38%)	Trading Strategy: Flag-formation breakout	SL: RM3.380 (-4.79%)
	R2: RM3.800 (+7.04%)	



**Technical Commentary:**

After bottoming out in August 2024, price formed a sharp rally before undergoing a corrective phase and erased most of its previous session gains to stabilise above SMA200. Following several weeks of consolidation, price formed a bullish candle to close above EMA120. Traders may anticipate a potential breakout above RM1.27 to target next resistances located at **RM1.31-RM1.35**. Downside wise, support is pegged at **RM1.22**.

<b>Duopharma Biotech Bhd (7148)</b>		
Board: MAIN	Shariah: Yes	Sector: Pharmaceuticals
Trend: ★★★★★	Momentum: ★★★★★	Strength: ★★★★★
R1: RM1.310 (+3.97%)	Trading Strategy: Monitor for breakout	SL: RM1.220 (-3.17%)
	R2: RM1.350 (+7.14%)	

**APEX SECURITIES BERHAD – CONTACT LIST**

<b>APEX SECURITIES BHD</b>	<b>DEALING TEAM</b>	<b>RESEARCH TEAM</b>
<p><b>Head Office:</b> 5th Floor Menara UAC, 12, Jalan PJU 7/5, Mutiar Damansara, 47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia</p> <p>General Line: (603) 7890 8899</p>	<p><b>Head Office:</b> Kong Ming Ming (ext 2002) Lee Chen Ming (ext 2029) Shirley Chang (ext 2026) Ahmad Mujib (ext 2028) Azfar Bin Abdul Aziz (ext 2031) Aizzat Bin Mohd Daud (ext 2030)</p> <p><b>Institutional Dealing Team:</b> Low Jin Wu (ext 2109)</p> <p><b>PJ Office:</b> General Line: (603) 7620 1118</p>	<p><b>Head Office:</b> Kenneth Leong (ext 2093) Steven Chong (ext 2068) Jayden Tan (ext 2069) Chelsea Chew (ext 2070) Tan Sue Wen (ext 2095) Ong Tze Hern (ext 2113) Samuel Woo (ext 2121) Amir Hamdan (ext 2112)</p>
<p><b>Petaling Jaya Office:</b> 16th Floor, Menara Choy Fook Onn, No.1B Jalan Yong Shook Lin, 46050 Petaling Jaya, Selangor Darul Ehsan, Malaysia</p> <p>General Line: (603) 7620 1118</p>		

**RESEARCH RECOMMENDATION FRAMEWORK**

**STOCK RECOMMENDATIONS**

**BUY:** Total returns\* are expected to exceed 10% within the next 12 months.  
**HOLD:** Total returns\* are expected to be within +10% to – 10% within the next 12 months.  
**SELL:** Total returns\* are expected to be below -10% within the next 12 months.  
**TRADING BUY:** Total returns\* are expected to exceed 10% within the next 3 months.  
**TRADING SELL:** Total returns\* are expected to be below -10% within the next 3 months.  
 \*Capital gain

**SECTOR RECOMMENDATIONS**

**OVERWEIGHT:** The industry defined by the analyst is expected to exceed 10% within the next 12 months.  
**NEUTRAL:** The industry defined by the analyst is expected to be within +10% to – 10% within the next 12 months.  
**UNDERWEIGHT:** The industry defined by the analyst, is expected to be below -10% within the next 12 months.

**DISCLAIMER**

Disclaimer: The report is for internal and private circulation only and shall not be reproduced either in part or otherwise without the prior written consent of Apex Securities Berhad. The opinions and information contained herein are based on available data believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell the securities covered by this report.

Opinions, estimates and projections in this report constitute the current judgment of the author. They do not necessarily reflect the opinion of Apex Securities Berhad and are subject to change without notice. Apex Securities Berhad has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

All analyst(s) names appear in the front page, whom prepared this report, does not have any interest in the following securities covered in this report.

Apex Securities Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Apex Securities Berhad. Apex Securities Berhad may from time to time have an interest in the company mentioned by this report. This report may not be reproduced, copied or circulated without the prior written approval of Apex Securities Berhad.